Published by DelveInsight - Leading companies include Trevi Therapeutics, Galderma, Genentech, Incyte Corporation, Vyne Therapeutics Inc., Celgene Corporation, Novartis, Pfizer, Regeneron Pharma, and others.
Market Overview
DelveInsight's comprehensive "Prurigo Nodularis Market Insights, Epidemiology, and Market Forecast-2034" delivers detailed analysis of this chronic inflammatory skin condition across major global markets including the United States, EU4 countries (Germany, Spain, Italy, France), United Kingdom, and Japan.
This extensive market analysis encompasses current therapeutic approaches, pipeline developments, individual therapy market shares, and projected market size from 2020 to 2034 across seven major markets. The report examines treatment algorithms, market catalysts, barriers, and unmet clinical needs while identifying optimal opportunities and assessing market potential.
To Know in detail about the Prurigo Nodularis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Prurigo Nodularis Market Forecast
Key Market Highlights
Market Growth & Size
Anticipated significant compound annual growth rate (CAGR) throughout the forecast period (2020-2034)
United States leads in diagnosed patient population among the 7 major markets as of 2023
Recent Regulatory Milestones
March 2025: Incyte Corporation reported positive outcomes from pivotal Phase 3 TRuE-PN clinical trials (TRuE-PN1 and TRuE-PN2), evaluating twice-daily ruxolitinib cream 1.5% (Opzelura®) in adult prurigo nodularis patients. Results were showcased at the 2025 American Academy of Dermatology Annual Meeting in Orlando.
February 2025: Galderma secured marketing authorization from UK Medicines and Healthcare products Regulatory Agency and Swissmedic for nemolizumab treatment of both atopic dermatitis and prurigo nodularis in the UK and Switzerland.
August 2024: FDA approved Galderma's Nemluvio® (nemolizumab) pre-filled pen for subcutaneous administration in adult prurigo nodularis patients. The therapy received Breakthrough Therapy Designation (December 2019) and Priority Review (February 2024).
March 2024: Incyte disclosed promising Phase II data for povorcitinib in prurigo nodularis treatment.
Epidemiological Insights
Prevalence rate: 3.27 cases per 10,000 patients (Morgan et al., 2022)
Gender distribution: Higher prevalence observed in females compared to males
Current FDA-approved treatment: DUPIXENT (dupilumab) remains the only approved therapy, creating substantial opportunities for emerging treatments
Understanding Prurigo Nodularis
Disease Characteristics
Prurigo Nodularis represents a chronic inflammatory dermatological condition featuring multiple, intensely pruritic, firm nodules resulting from persistent scratching and skin trauma. While the precise etiology remains undefined, the condition correlates with immune dysfunction, chronic pruritus, neurological abnormalities, and comorbid conditions including atopic dermatitis, diabetes, chronic kidney disease, HIV, and psychiatric disorders.
Clinical Presentation
Patients experience severe, continuous pruritus leading to excoriated, hyperpigmented, or lichenified nodules primarily affecting extremities and trunk. The perpetual itch-scratch cycle exacerbates the condition, creating therapeutic challenges and significantly impacting quality of life through sleep disruption, psychological distress, and social stigma.
Diagnostic Approach
Clinical diagnosis relies on characteristic nodular presentation and patient history, potentially supplemented by skin biopsies, laboratory studies, or neurological assessments to exclude underlying pathology.
Treatment Strategies
Current management focuses on interrupting the itch-scratch cycle using topical corticosteroids, calcineurin inhibitors, antihistamines, and moisturizers. Severe cases may require biologic therapies (IL-31 inhibitors), immunosuppressive agents, gabapentinoids, and phototherapy. Recent advances in targeted biologics and neuromodulators offer enhanced therapeutic outcomes and sustained disease management.
Get a Free sample for the Prurigo Nodularis Market Report: https://www.delveinsight.com/report-store/prurigo-nodularis-market
Epidemiological Analysis
Market Segmentation (2020-2034)
Our epidemiological assessment across the 7MM includes:
Overall prurigo nodularis prevalence
Severity-stratified patient populations
Gender-specific prevalence patterns
Episodic versus chronic disease classifications
Download the report to understand which factors are driving Prurigo Nodularis epidemiology trends @ Prurigo Nodularis Epidemiology Forecast
Pipeline Development & Drug Uptake Analysis
Market Dynamics Assessment
The drug uptake analysis evaluates adoption rates for recently launched and anticipated therapies, examining market penetration by therapeutic agents, patient adoption patterns, and individual drug sales performance. This assessment identifies rapid-uptake therapies and underlying adoption drivers while providing comparative market share analysis.
Pipeline Development Activities
Our analysis covers therapeutic candidates across development stages, key pharmaceutical companies, and recent strategic developments including collaborations, acquisitions, mergers, licensing agreements, and patent activities for emerging therapies.
Leading Therapies & Companies
Key Market Players & Their Treatments:
Nalbuphine ER - Trevi Therapeutics
Nemolizumab - Galderma
Vixarelimab (KPL-716) - Genentech
Povorcitinib (INCB-54707) - Incyte Corporation
Ruxolitinib Cream - Incyte Corporation
INCB054707 - Incyte Corporation
Serlopitant - Vyne Therapeutics Inc.
CC-10004 - Celgene Corporation
Pimecrolimus - Novartis
Abrocitinib - Pfizer
Dupilumab SAR231893 - Regeneron Pharma
Discover more about therapies set to grab major Prurigo Nodularis market share @ Prurigo Nodularis Treatment Market
Market Strengths & Opportunities
Competitive Advantages
Innovative drug formulations are transforming market prospects and patient quality of life for those suffering from chronic neurologically-mediated conditions with limited treatment alternatives. Vixarelimab's dual mechanism presents promising potential for both pruritus relief and nodule improvement.
Growth Opportunities
Expanding patient populations create significant opportunities for increased awareness and therapeutic innovation. With only one currently approved therapy, substantial market potential exists for companies developing novel emerging treatments.
Report Scope & Coverage
Study Parameters
Analysis Period: 2020–2034
Geographic Coverage: 7MM [United States, EU5 (Germany, France, Italy, Spain, United Kingdom), Japan]
Therapeutic Assessment: Current marketed and emerging prurigo nodularis therapies
Market Dynamics: Comprehensive analysis of drivers and barriers
Competitive Intelligence: SWOT, PESTLE, Porter's Five Forces, BCG Matrix, Market Entry Strategies
Additional Insights: Unmet needs, KOL perspectives, market access and reimbursement analysis
To know more about Prurigo Nodularis companies working in the treatment market, visit @ Prurigo Nodularis Clinical Trials and Therapeutic Assessment
Comprehensive Report Structure
Market Introduction & Executive Summary
SWOT Analysis
Patient Share Overview
Market Overview at a Glance
Disease Background & Overview
Epidemiology & Patient Population Analysis
Country-Specific Patient Demographics
Current Treatment Practices
Unmet Medical Needs
Emerging Therapeutic Landscape
Market Outlook & Forecasting
Country-Wise Market Analysis (2020–2034)
Market Access & Reimbursement
Market Drivers & Barriers Analysis
Methodology & Capabilities
About DelveInsight
DelveInsight stands as a premier Healthcare Business Consultant and Market Research organization specializing exclusively in life sciences. We deliver comprehensive end-to-end solutions designed to enhance pharmaceutical company performance and strategic decision-making.
Contact Information
Kanishk
kkumar@delveinsight.com
info@delveinsight.com
+14699457679
